TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
For patients with advanced HCC not suitable for resection or liver transplantation but
without extrahepatic manifestations, local therapy with TACE is regarded as standard
treatment. The present study is planned to evaluate the combination of TACE and sorafenib. A
combination of TACE with a multitarget inhibitor like sorafenib may further improve the
outcome of patients with HCC.